北京科鋭(002350.SZ):收到與收益相關的政府補助資金共計200萬元
格隆匯6月27日丨北京科鋭(002350.SZ)公佈,公司於2022年3月1日完成以自有資金13,770萬元通過股權轉讓及增資方式投資北京穩力科技有限公司的工商變更手續,根據《中關村國家自主創新示範區促進科技金融深度融合發展支持資金管理辦法(試行)》及北京市科學技術委員會、中關村科技園區管理委員會《關於徵信2023年度新三板掛牌、併購支持資金項目的通知》的有關規定,公司申報了併購支持資金項目,並於近日收到與收益相關的政府補助資金共計人民幣200萬元,佔公司2022年度經審計歸屬於上市公司股東淨利潤的12.79%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.